Zentalis Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
ZNTL$1.80+3.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statement of Stockholders’ Equity
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands)
| Three Months Ended March 31, 2024 | |||||||
|---|---|---|---|---|---|---|---|
| Common · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income · AccumulatedDeficit · NoncontrollingInterests · TotalEquity | |||||||
| Shares · Amount | |||||||
| Balance at December 31, 2023 | 70,767 | $70 | $1,323,576 | $2,194 | $(888,556) | $107 | $437,391 |
| Share-based compensation expense | — | — | 12,833 | — | — | — | 12,833 |
| Other comprehensive loss | — | — | — | (1,421) | — | — | (1,421) |
| Issuance and withholding of common stock in connection with restricted stock unit vesting, net | 228 | — | (241) | — | — | — | (241) |
| Deconsolidation of Kalyra | — | — | — | — | — | (79) | (79) |
| Shares issued under employee stock purchase plan | 18 | — | 248 | — | — | — | 248 |
| Net loss attributable to non-controlling interest | — | — | — | — | — | (28) | (28) |
| Net income attributable to Zentalis | — | — | — | — | 10,068 | — | 10,068 |
| Balance at March 31, 2024 | 71,013 | $70 | $1,336,416 | $773 | $(878,488) | $— | $458,771 |
| Three Months Ended March 31, 2023 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Common · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income · AccumulatedDeficit · NoncontrollingInterests · TotalEquity | |||||||||
| Shares · Amount | |||||||||
| Balance at December 31, 2022 | 59,280 | $59 | $1,031,462 | $(1,353) | $(596,365) | $221 | $434,024 | ||
| Share-based compensation expense | — | — | 13,733 | — | — | — | 13,733 | ||
| Other comprehensive income | — | — | — | 797 | — | — | 797 | ||
| Issuance of common stock in connection with restricted stock unit vesting | 139 | — | — | — | — | — | — | ||
| Shares issued under employee stock purchase plan | 25 | — | 373 | — | — | — | 373 | ||
| Cancellation of restricted stock awards | (2) | — | — | — | — | — | |||
| Net loss attributable to non-controlling interest | — | — | — | — | (43) | (43) | |||
| Net loss attributable to Zentalis | — | — | — | — | (63,219) | — | (63,219) | ||
| Balance at March 31, 2023 | 59,442 | $59 | $1,045,568 | $(556) | $(659,584) | $178 | $385,665 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.